<DOC>
	<DOCNO>NCT00809484</DOCNO>
	<brief_summary>To investigate management bone health postmenopausal woman early breast cancer ( BCA ) schedule receive anastrozole . Postmenopausal woman hormone receptor-positive early BCA assign 1 3 stratum depend pre-existing risk fragility fracture . Patients ( pt ) bone mineral density ( BMD ) T-score &lt; -2.0 either spine hip designate higher-risk ( H ) fracture receive anastrozole 1 mg/day plus risedronate orally . Moderate-risk ( M ) pt ( T-score &lt; -1.0 spine hip -2.0 sit ) randomize receive anastrozole plus risedronate ( A+R ) anastrozole alone . Pts T-scores -1.0 spine hip designate lower-risk ( L ) receive anastrozole alone . All pt receive calcium vitamin D. Lumbar spine total hip BMD assess baseline , 12 , 24 month .</brief_summary>
	<brief_title>Arimidex Bone Mass Index Oral Bisphosphonates</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Postmenopausal woman ER PgR positive breast cancer Completed Surgery =/ chemotherapy metastases history fracture HRT SERMs Liver kidney disfunction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Arimidex</keyword>
	<keyword>Bone Mineral density</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Aromatase Inhibitors</keyword>
</DOC>